[1]吴 斐,曾 倩,崔文军,等.药物涂层球囊联合斑块旋切术治疗股浅动脉支架内再闭塞 [J].介入放射学杂志,2021,30(05):508-511.
WU Fei,ZENG Qian,CUI Wenjun,et al.Drug-coated balloon angioplasty combined with directional atherectomy for the treatment of superficial femoral artery in-stent re-occlusion[J].journal interventional radiology,2021,30(05):508-511.
点击复制
药物涂层球囊联合斑块旋切术治疗股浅动脉支架内再闭塞 ()
《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]
- 卷:
-
30
- 期数:
-
2021年05
- 页码:
-
508-511
- 栏目:
-
临床研究
- 出版日期:
-
2021-05-25
文章信息/Info
- Title:
-
Drug-coated balloon angioplasty combined with directional atherectomy for the treatment of superficial femoral artery in-stent re-occlusion
- 作者:
-
吴 斐; 曾 倩; 崔文军; 王 兵
-
- Author(s):
-
WU Fei; ZENG Qian; CUI Wenjun; WANG Bing.
-
Department of Vascular Surgery, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450052, China
-
- 关键词:
-
【关键词】 股浅动脉; 支架内再闭塞; 药物涂层球囊
- 文献标志码:
-
A
- 摘要:
-
【摘要】 目的 评价药物涂层球囊(DCB)联合TurboHawk定向斑块旋切术(DA)治疗股浅动脉支架内再闭塞的近中期效果。 方法 回顾性分析2016年8月至2018年8月在郑州大学第五附属医院接受血管内治疗的36例股浅动脉支架内再闭塞患者临床资料。其中19例接受DCB联合DA治疗,17例接受普通球囊血管成形术(POBA)联合DA治疗。对比两组近中期临床疗效。结果 两组患者手术均获成功,平均随访(11.28±1.63)(9~15)个月。DCB+DA组术后6个月靶血管一期通畅率与POBA+DA组差异无统计学意义[94.7%(18/19)对82.4%(14/17),P>0.05],术后12个月一期通畅率高于POBA+DA组[89.5%(17/19)对64.7%(11/17),P=0.029]。两组患者术后6个月最小管腔直径(MLD)差异无统计学意义(P>0.05)。术后12个月DCB+DA组患者MLD显著高于POBA+DA组(P=0.029),远期管腔丢失(LLL)显著低于POBA+DA组(P=0.018)。 结论 DCB联合DA治疗股浅动脉支架内再闭塞具有较好的近中期效果。
参考文献/References:
[1] Norgren L, Hiatt WR, Dormandy JA,et al. Inter- Society Consensus for the Management of Peripheral Arterial Disease(TASC II)[J]. J Vasc Surg, 2007, 45(Suppl S): S5- S67.
[2] 吴 斐,刘俊超,王洛波,等. 杂交技术治疗复杂下肢动脉硬化闭塞症疗效分析[J]. 中国普通外科杂志, 2015, 24:1683- 1686.
[3] 潘锦轩. 药物涂层球囊应用于股浅动脉支架内再狭窄的疗效分析[D]. 郑州:郑州大学, 2019.
[4] 刘晓哲,王 兵,刘俊超,等. 药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用[J]. 介入放射学杂志, 2018, 27:410- 414.
[5] Janas A,Buszman PP,Milewski KP,et al. Long- term outcomes after percutaneous lower extremity arterial interventions with atherectomy vs. balloon angioplasty- propensity score- matched registry[J]. Circ J, 2017, 81:376- 382.
[6] Brodmann M, Rief P, Froehlich H, et al. Neointimal hyperplasia after silverhawk atherectomy versus percutaneous transluminal angioplasty(PTA) in femoropopliteal stent reobstructions:a cont- rolled, randomized pilot trial[J]. Cardiovasc Intervent Radiol, 2013, 36: 69- 74.
[7] Schnorr B, Albrecht T. Drug- coated balloons and their place in treating peripheral arterial disease[J]. Expert Rev Med Devices, 2013, 10: 105- 114.
[8] 崔文军,王 兵,安 乾,等. 斑块旋切术联合药物涂层球囊治疗股腘动脉硬化闭塞症[J]. 实用医学杂志, 2018, 34:4106- 4109.
[9] 贺 艺,王 兵. 股腘动脉支架内再狭窄的腔内治疗进展[J].中国普通外科杂志, 2019, 28:749- 755.
[10] 蔡志文,谷涌泉. 定向斑块旋切联合药物涂层球囊治疗股腘动脉病变进展[J]. 介入放射学杂志, 2019, 28:301- 304.
[11] Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro- popliteal lesions using directional atherec- tomy and a paclitaxel coated balloon: one- year single centre clinical results[J]. Cardiovasc Revasc Med, 2012, 13: 219- 223.
[12] Sixt S, Carpio Cancino OG, Treszl A, et al. Drug- coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries[J]. J Vasc Surg, 2013, 58: 682- 686.
[13] Grotti S, Liistro F, Angioli P, et al. Paclitaxel- eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in- stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE- ISR study[J]. J Endovasc Ther, 2016, 23: 52- 57.
备注/Memo
- 备注/Memo:
-
(收稿日期:2020- 02- 18)
(本文编辑:边 佶)
更新日期/Last Update:
2021-05-20